Chira et al. proposeda novel andhighly tumor-specific TP53 delivery system basedon CRISPR/Cas9 genome editing technology, which can be used to replacethe mutant TP53 in the tumor genome with a functionalcopy by homologous recombination, leading to sustained expressionof p53 protein and tumor regression. This evidence concerns the gene TP53 and neoplasm.